EOLS is trading down about -8.75% to roughly $7.82 during regular market hours, versus a prior-session close of $8.57. The slide extends a multi-day pullback from its 52-week high near $9.31, leaving shares roughly -16% below that recent peak.

ALM fell -8.57% to roughly $16.76 during regular trading, down from a $18.33 prior-session close. The decline occurred intraday, extending the prior session's -4.13% drop as the stock pulls back from its $24.41 52-week high.

LECO fell -8.60% (-$23.34) to about $248.18 during Thursday's regular session, on pace for its largest one-day drop since April 2025. The primary catalyst was cautious commentary at the Jefferies Global Industrials Conference, where management signaled Q3 incremental margins tracking in the "low 20s," down from prior "mid-20s" guidance.

AXGN fell -9.92% to $42.58 during regular trading, from a prior-session close of $47.27. Primary catalyst: the company priced a 4.91M-share underwritten public offering at $42.50, a >10% discount that dilutes existing shareholders.

AEO is down -15.51% to about $14.27, versus a prior close of $16.89. The stock gapped lower in premarket and continued falling during the regular session after Q2 FY2026 results released Wednesday post-close.

BHVN dropped -15.93% to $12.61 during regular trading, after the FDA disclosed a partial clinical hold on its BHV-7000 epilepsy program. The decline began premarket as Biohaven revealed the FDA paused new patient enrollment in the Phase 2/3 trial after rodent studies flagged a potentially toxic drug metabolite.

Tenon Medical (TNON) shares have fallen roughly 60% over the past 30 days, closing at $2.44 on September 9, 2026, down from $6.14 in early August. The move reflects a 1-for-35 reverse stock split, continued share dilution, and a second-quarter earnings miss, only partly offset by the full repayment of convertible notes.

BKR is down -5.23% during regular trading, falling to about $60.31 from a prior close of $63.64. The selloff tracked crude oil dropping to its lowest since the start of the Iran conflict, as tankers resumed Strait of Hormuz transit and U.S.-Iran signaled de-escalation progress.

VRT is down -5.24% in regular trading, near $249 versus a prior-session close of $262.89, extending yesterday's -9.6% slide. The drop reflects follow-through profit-taking and a valuation reset across AI-infrastructure names, with no new company-specific filing driving the move.

ATNM is up +8.94% intraday, trading near $1.34 versus a prior close of $1.23, with the move occurring during regular market hours. The gain extends a multi-day rally following positive Phase 3 SIERRA data for Iomab-B in relapsed/refractory AML, which met its primary endpoint of durable complete remission.

LRCX is down -5.12% to roughly $299.66 in regular trading, versus a prior close of $315.84. Primary catalyst: Kioxia CEO Hiroo Ota said memory prices have "risen enough," warning further hikes could curb AI investment—spooking memory and chip-equipment names.

INTC closed up +1.69% to $106.24 during regular trading, extending the prior session's +9.05% surge to $104.47. Buying followed reports Intel may raise PC CPU prices roughly 10% in October, a third 2026 hike signaling pricing power amid chip shortages.

NAVN is down -20.93% today, sliding from a $25.89 prior close to about $20.47 intraday, extending a sharp post-earnings selloff. The decline began after-hours on Sept. 9, when shares fell roughly -15% following Navan's fiscal Q2 2027 results, and continued into the regular session.

COO is down -15.5% to roughly $53.64, extending a -6.2% drop in Wednesday's regular session after reporting fiscal Q3 results after the close. The primary catalyst was a Q3 revenue miss ($1.066B vs. ~$1.098B consensus) driven by CooperVision's U.S. channel inventory destocking.

Ondas Holdings (ONDS) shares fell roughly 25% over the trailing 30 days, sliding from a closing price of about $9.74 on August 11 to $7.29 on September 9, 2026. The decline unfolded despite record second-quarter revenue of $83.8 million (up more than 13x year over year) and an increase in full-year guidance to $525–$550 million.

Carpenter Technology (CRS) shares fell about 18.1% over the trailing 30 days, from roughly $559.75 on August 10 to $458.45 at the September 9 close, despite record fiscal fourth-quarter results. The decline followed the company's fiscal Q4 2026 report, which beat on earnings per share ($3.23 versus the $3.08 consensus) but posted revenue of $851.0 million, slightly below the $863.3 million estimate.

Credo Technology (CRDO) declined roughly 32% over the 30 days ending in early September 2026, despite delivering record quarterly results. The selloff followed a "beat-and-raise" fiscal Q1 2027 report, as investors focused on narrowing margins and heavy customer concentration rather than surging revenue.

TJX shares fell roughly 19% over the trailing 30 days, from about $155.74 to $126.12, extending a decline from the stock's June peak near $170. The selloff was triggered by the fiscal 2027 second-quarter earnings report released August 19, when near-term third-quarter guidance landed below analyst expectations.

RKLB fell roughly 21% over the last 30 days, from about $80 to the low-$60s, extending a multi-month pullback from its 52-week high. The decline came even as the company reported record second-quarter revenue of $234.1 million, up 62% year over year, and a record $2.36 billion backlog.

The central question is whether Summit Therapeutics (SMMT) can reclaim the $30 level, roughly 71% above its recent price near $17.54. The strongest bullish case rests on ivonescimab, a Phase III oncology drug candidate with a pivotal lung cancer readout expected in the second half of 2026.